Latest KFF Health News Stories
Klobuchar Says D.C. Has Enough Drug Lobbyists To Double-Team Lawmakers
The drug industry has the biggest lobbying war chest.
GOP Senators Distance Themselves From Grassley And Trump’s Efforts To Cut Drug Prices
Even some Republicans who supported a sweeping bipartisan bill to rein in drug costs may not back it in the Senate vote.
KHN’s ‘What The Health?’: Cue The Drug Price Debate
Democrats and Republicans on the Senate Finance Committee unveiled their long-awaited proposal to try to rein in prescription drug costs, even as bipartisan leaders of the other Senate committee that oversees health announced it would not bring its drug price bill to the Senate floor until fall. Paige Winfield Cunningham of The Washington Post, Rebecca Adams of CQ Roll Call and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss this, plus court actions on health issues.
A Conservative Group Paints Trump’s Drug-Pricing Experiment As ‘Socialist.’ Is It?
The Americans for Tax Reform commercial takes too broad a brush against an initiative under consideration by the administration that would be part of the president’s promise to curb high drug prices.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
KHN’s ‘What The Health?’: Biden Doubles Down On Obamacare
Presidential candidate Joe Biden unveiled a health plan intended to provide a more moderate alternative to his competitors’ “Medicare for All” plans. It would build on the Affordable Care Act but would go much further. Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and Kimberly Leonard of the Washington Examiner join KHN’s Julie Rovner to discuss this, plus Planned Parenthood’s very bad week, the U.S. House vote to repeal the health law’s “Cadillac tax” on generous health plans, and the reduction in deaths from opioids.
A ‘No-Brainer’? Calls Grow For Medicare To Cover Anti-Rejection Drugs After Kidney Transplant
Banking on new cost estimates, a bipartisan coalition in Congress is poised to try — once again — to end a three-year limit on coverage for lifesaving medication required to keep the organs functioning.
Costos adicionales bloquean el tratamiento para prevenir el VIH
Aunque muchas aseguradoras cubren PrEP, los costos por las pruebas adicionales que hay que realizarse pueden bloquear el acceso a esta terapia preventiva.
Even When HIV Prevention Drug Is Covered, Other Costs Block Treatment
The U.S. Preventive Services Task Force recommended that people who are at high risk of contracting HIV take PrEP, a preventive treatment. The decision means most health plans will be required to cover the drugs without charging patients. But the recommendation doesn’t apply to the other clinical and lab services people need.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
KHN’s ‘What The Health?’: Could The ACA Really Go Away?
Is the entire Affordable Care Act unconstitutional? That was the question before a federal appeals court in New Orleans this week. Two of the three judges on the panel seemed inclined to agree with a lower court that the elimination of the tax penalty for failure to maintain coverage could mean the entire health law should fall. Also this week, President Donald Trump wants to improve care for people with kidney disease. Joanne Kenen of Politico, Kimberly Leonard of the Washington Examiner and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss this, plus courts blocking efforts to require drug prices in TV ads and to kick Planned Parenthood out of the federal family planning program. Plus, Rovner interviews University of Michigan law professor Nicholas Bagley about the latest legal threat to the ACA.
Watch: High Cost Of Insulin Sends Americans To Canada To Stock Up
KHN, in collaboration with PBS NewsHour, reports on the skyrocketing cost of insulin — and the trend’s deadly consequences. The price in the U.S. nearly doubled from 2012 to 2016, prompting some patients and activists to travel to Canada, where insulin can be 90% cheaper.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
Pelosi Aims For Feds To Negotiate Drug Prices, Even For Private Insurers
A draft plan spearheaded by House Speaker Nancy Pelosi would allow the federal government for the first time to negotiate prices for 250 drugs for Medicare and apply those prices to all payers, including employers and insurers.
Trump Has Blessed States’ Exploration Of Importing Drugs. Will It Catch On?
Colorado, Florida and Vermont — with the support of President Donald Trump — are exploring plans to bring drugs across the border from Canada to help lower costs.
KHN’s ‘What The Health?’: Dems Debate Health Care
Democratic presidential candidates disagreed on how to fix health care in their first debate Wednesday, although they all called for boosting insurance coverage and lowering prices. Meanwhile, the Trump administration is keeping health care in the news, too, with a new plan to make medical prices more available to the public. Stephanie Armour of The Wall Street Journal, Rebecca Adams of CQ Roll Call and Anna Edney of Bloomberg News join KHN’s Julie Rovner to discuss this, plus the latest in news about bipartisan progress on catch-all legislation to address “surprise” medical bills. Plus, Rovner interviews NPR’s Jon Hamilton about the latest KHN-NPR “Bill of the Month” installment.
‘Medicare For All’ Emerges As Early Divide In First Democratic Debate
On the first of the Democrat’s two-night debate, only New York City Mayor Bill de Blasio and Massachusetts Sen. Elizabeth Warren offered full support for a single-payer system that would banish private health insurance.
‘An Arm And A Leg’: Why Are Drug Prices So Random? Meet Mr. PBM
Beware at the pharmacy counter: Your insurance company could be in cahoots with a pharmacy benefit manager — and the negotiations that go on between them are trade secrets.
Middlemen Who Save $$ On Medicines — But Maybe Not For You
Guess who’s back grabbing headlines? Pharmacy benefit managers — those companies that serve as middlemen in the prescription drug pipeline.
Julie Rovner, the chief Washington correspondent for Kaiser Health News, joins Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and Alan Weil of Health Affairs at the Aspen Ideas: Health festival to discuss how consumers’ values impact the politics surrounding the national debate on health care.
